Company

Serif Biomedicines, Inc.

Serif Biomedicines develops genetic medicines using programmed nucleic acids.

About

Founded in 2021 and based in Cambridge, US, Serif Biomedicines develops modified DNA molecules designed to function as therapeutic agents. Its work is aimed at pharmaceutical companies and research institutions. In April 2026, it raised USD 50.00 mn from Flagship Pioneering to develop its platform and initial drug discovery programs.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in